Poolbeg Pharma (POLB) Competitors GBX 8.30 +0.30 (+3.75%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades POLB vs. CIR, SCLP, FUM, TILS, VSN, MPH, ORPH, REDX, ETX, and TRXShould you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Circassia Group (CIR), Scancell (SCLP), Futura Medical (FUM), Tiziana Life Sciences (TILS), Verseon (VSN), Mereo BioPharma Group plc (MPH.L) (MPH), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), and Tissue Regenix Group (TRX). These companies are all part of the "biotechnology" industry. Poolbeg Pharma vs. Circassia Group Scancell Futura Medical Tiziana Life Sciences Verseon Mereo BioPharma Group plc (MPH.L) Open Orphan Redx Pharma e-therapeutics Tissue Regenix Group Poolbeg Pharma (LON:POLB) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings. Does the media refer more to POLB or CIR? In the previous week, Poolbeg Pharma had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Circassia Group. Poolbeg Pharma's average media sentiment score of 0.67 beat Circassia Group's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media. Company Overall Sentiment Poolbeg Pharma Positive Circassia Group Neutral Does the MarketBeat Community prefer POLB or CIR? Circassia Group received 125 more outperform votes than Poolbeg Pharma when rated by MarketBeat users. CompanyUnderperformOutperformPoolbeg PharmaN/AN/ACircassia GroupOutperform Votes12571.43% Underperform Votes5028.57% Which has higher earnings and valuation, POLB or CIR? Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPoolbeg PharmaN/AN/A-£4.38M-£0.01-830.00Circassia Group£27.90M5.11N/A£0.013,400.00 Is POLB or CIR more profitable? Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Poolbeg PharmaN/A -30.18% -21.33% Circassia Group N/A N/A N/A Do analysts recommend POLB or CIR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Poolbeg Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACircassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do institutionals & insiders have more ownership in POLB or CIR? 1.2% of Poolbeg Pharma shares are held by institutional investors. 24.7% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCircassia Group beats Poolbeg Pharma on 6 of the 10 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Poolbeg Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POLB vs. The Competition Export to ExcelMetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£41.50M£159.96M£5.40B£1.58BDividend YieldN/A3.39%5.13%11.08%P/E Ratio-830.00348.23115.481,723.54Price / SalesN/A19,593.141,483.20228,959.04Price / Cash2.1111.1439.6535.69Price / Book2.777.754.662.87Net Income-£4.38M-£18.69M£119.06M£144.80M7 Day Performance4.86%0.01%0.80%0.11%1 Month Performance-7.79%2.54%5.66%-0.16%1 Year Performance22.06%27.91%36.76%15.21% Poolbeg Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POLBPoolbeg PharmaN/AGBX 8.30+3.8%N/A+27.7%£41.50MN/A-830.0012Gap UpCIRCircassia GroupN/AGBX 34-6.8%N/A+0.0%£142.66M£27.90M3,400.00111Gap DownSCLPScancellN/AGBX 14.51+1.8%N/A+10.1%£134.84M£5.27M-1,450.5051News CoverageFUMFutura MedicalN/AGBX 38.68+13.7%N/A+28.8%£116.95M£8.40M-3,867.5012News CoverageGap UpHigh Trading VolumeTILSTiziana Life SciencesN/AN/AN/A+0.0%£113.85M£-3,595,000.00-3.5911News CoverageVSNVerseonN/AN/AN/A+0.0%£112.24MN/A-5.17N/ANews CoverageGap UpMPHMereo BioPharma Group plc (MPH.L)N/AGBX 26.50-1.9%N/A+0.0%£89.76MN/A-0.2150Gap DownORPHOpen OrphanN/AGBX 10+5.3%N/AN/A£67.09M£34.71M-25.30179REDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AGBX 9-6.7%N/A-2.6%£52.59M£295,000.00-450.0035News CoverageHigh Trading VolumeTRXTissue Regenix GroupN/AGBX 54flatN/A+7.9%£38.46M£31.80M-5,400.00120Gap Down Related Companies and Tools Related Companies CIR Competitors SCLP Competitors FUM Competitors TILS Competitors VSN Competitors MPH Competitors ORPH Competitors REDX Competitors ETX Competitors TRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:POLB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
